SMAD3 and breast cancer: In summary, we hypothesize that the progressive loss of WWOX expression in advanced breast cancer contributes to deregulating the TGFβ pathway and, more importantly, may explain some of the pro-metastatic effects resulting from TGFβ/SMAD3 hyperactive signaling in advanced breast cancer.